When standard antidepressants have not brought enough relief, the question often becomes more specific: what comes next, and which option actually fits your life? For many people with treatment-resistant depression, the comparison of TMS vs Spravato for depression is not just academic. It is a practical decision about safety, schedule, side effects, and the kind of improvement they hope to feel.
Both treatments are FDA-approved options used in interventional psychiatry. Both can be valuable for people whose depression has persisted despite medication trials. But they are not interchangeable, and the best choice depends on your symptoms, medical history, treatment goals, and day-to-day responsibilities.
TMS vs Spravato for depression: the basic difference
Transcranial Magnetic Stimulation, or TMS, is a noninvasive treatment that uses targeted magnetic pulses to stimulate brain regions involved in mood regulation. It does not require anesthesia, and patients remain awake and alert during treatment. A typical course involves repeated sessions over several weeks.
Spravato is the brand name for intranasal esketamine. It is a prescription medication derived from ketamine and is administered in a certified medical setting under supervision. After each treatment, patients are monitored for a period of time because the medication can temporarily affect blood pressure, perception, and alertness.
At a high level, TMS works through external magnetic stimulation, while Spravato works through medication effects on brain signaling. That distinction shapes nearly everything else, from side effects to logistics.
How TMS works
TMS targets specific cortical areas associated with depression, most commonly the left dorsolateral prefrontal cortex. The treatment uses magnetic energy to activate underactive neural circuits involved in mood, motivation, and emotional processing.
Patients typically sit in a treatment chair while a device is positioned against the scalp. Sessions are brief, and because there is no sedation, most people can drive themselves to and from treatment and return to work or errands afterward.
For patients who want an option that does not add another daily medication to the mix, that can be a meaningful advantage. TMS is also appealing to people who have struggled with medication side effects such as weight gain, sexual side effects, sedation, or gastrointestinal symptoms.
How Spravato works
Spravato affects glutamate signaling in the brain, which is different from how most standard antidepressants work. That difference matters because many traditional antidepressants primarily target serotonin, norepinephrine, or dopamine and may not help everyone with treatment-resistant depression.
Spravato is self-administered as a nasal spray in the clinic under medical supervision, then followed by a monitoring period. Patients cannot drive themselves home after treatment, so transportation planning is part of the process.
One reason Spravato gets attention is that some patients notice improvement relatively quickly compared with standard antidepressants. That does not mean it works instantly for everyone, and it does not mean TMS works too slowly to be useful. It simply means the time course can differ, and in some clinical situations, speed matters.
Which treatment may work faster?
This is one of the most common questions, and the honest answer is: it depends.
Some patients receiving Spravato report early improvement in mood, hopelessness, or suicidal thinking within days to weeks. That potential for faster symptom relief is one reason it may be considered in carefully selected cases.
TMS often builds more gradually over a series of treatments. Many patients begin noticing changes after a few weeks, though some respond sooner and others later. The improvement can show up first in subtle ways, such as better sleep, less mental heaviness, or more ability to get through the day.
If someone is in urgent distress, the speed of response may weigh more heavily in treatment planning. If someone is focused on minimizing medication exposure or avoiding dissociative effects, TMS may feel like the better fit even if it requires more patience.
Side effects and tolerability
The side effect profile is often where the choice becomes clearer.
TMS is generally well tolerated. The most common side effects are scalp discomfort, headache, or facial muscle twitching during treatment. These effects are usually mild and often improve as treatment continues. Serious risks are uncommon, but seizure risk, while rare, is part of informed consent and medical screening.
Spravato has a different side effect pattern. Patients may experience dizziness, dissociation, nausea, sedation, increased blood pressure, or a sense of feeling detached or unusual for a period after dosing. Because of these effects, treatment must take place in a supervised setting with observation afterward.
Neither option is universally easier. Some patients strongly prefer a nonmedication approach and are comfortable with frequent visits for TMS. Others find the monitored clinic-based structure of Spravato reassuring and are less bothered by temporary medication effects than by the idea of daily or near-daily sessions.
Practical lifestyle differences
Comparing TMS vs Spravato for depression is also a matter of logistics.
TMS is usually delivered five days per week during the acute phase of treatment. That schedule can be demanding, especially for people balancing work, childcare, or a long commute. The upside is that sessions are relatively short, and patients can usually resume normal activities immediately afterward.
Spravato appointments are less frequent in the long term, but each visit takes more time because of administration and monitoring requirements. Patients also need someone to drive them home. For some people, that transportation issue is a major barrier. For others, fewer treatment days make Spravato more manageable overall.
This is why a treatment that looks ideal on paper may not be ideal in real life. A plan only helps if you can realistically follow through with it.
Who may be a better candidate for TMS?
TMS may be a strong option for patients with treatment-resistant depression who want an FDA-cleared therapy that does not involve systemic medication side effects or post-treatment sedation. It can be especially appealing for people who need to remain functional during the workday, care for family members, or avoid treatments that require a ride home.
It may also be worth considering for patients who have not tolerated antidepressants well, or for those who prefer a treatment that is targeted and noninvasive.
At Brainiac Behavioral Health, TMS is available in Anaheim Hills, which can be helpful for patients looking for a structured outpatient option in that area.
Who may be a better candidate for Spravato?
Spravato may be a good fit for adults with treatment-resistant depression who are appropriate for esketamine treatment and can participate in the required in-office monitoring. It may also be considered when a clinician is looking for an evidence-based option that works through a different biological pathway than standard antidepressants.
Patients who have support with transportation and who are comfortable with supervised medication-based treatment may find Spravato to be a practical and promising option. At this practice, Spravato is available in Orange and Anaheim Hills, giving some patients more flexibility in where they receive care.
The role of psychiatric evaluation
The most useful comparison is not just TMS versus Spravato in general. It is TMS versus Spravato for you.
Depression is not one-size-fits-all. Some patients have prominent anxiety, agitation, or insomnia. Others are dealing with emotional numbness, cognitive slowing, trauma history, bipolar spectrum features, substance use concerns, or other medical factors that change the risk-benefit discussion. A careful psychiatric evaluation helps clarify diagnosis, past treatment response, medication history, and whether either treatment needs extra caution.
That evaluation also matters because treatment-resistant depression can overlap with other conditions. If the diagnosis is incomplete, even advanced treatment may miss the mark. Good care starts with getting the clinical picture right.
What if you are unsure which one to choose?
That uncertainty is common, especially if you have already been disappointed by prior treatments. Many patients worry about choosing wrong, wasting time, or getting their hopes up again.
The better frame is not finding a perfect treatment on the first try. It is making a thoughtful decision based on evidence, medical fit, and what you can realistically sustain. In some cases, one option stands out clearly. In others, both are reasonable and the decision comes down to side effect preference, scheduling, transportation, symptom urgency, and prior treatment history.
What matters most is having a team that can walk you through the trade-offs honestly. Compassionate, science-backed care should leave room for questions, concerns, and a plan that feels manageable.
If you are weighing next steps after antidepressants have not done enough, there is real value in asking for a formal consultation rather than trying to sort through everything alone. The right treatment can help restore balance, clarity, and hope, but it starts with choosing the option that fits your clinical needs and your life.